Proteasome inhibitor drugs on the rise

Cancer Research

Volumn 66, Issue 16, 2006, Pages 7840-7842

  Joazeiro, Claudio A P ^a,d   Anderson, Kenneth C ^c   Hunter, Tony ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Genomic Institute of the Novetis Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; EPOXOMICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LACTACYSTIN; LENALIDOMIDE; NPI 0052; PR 171; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; UBIQUITIN; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKEMIA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748075461     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2033     Document Type: Conference Paper

References (8)

1. Kisselev AF, Goldberg A. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8: 739-58.
2. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH, The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 1997;272:25200-9.
3. Kisselev AF, Callard A, Goldberg A. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006;281:8582-90.
4. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65:11658-66.
5. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
6. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 2003;348:2609-17.
7. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003;42:355-7.
8. Chauhan D, Catley L, Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005;8:407-19.